TY - JOUR
T1 - Radiological biomarkers for diagnosis in PSP
T2 - Where are we and where do we need to be?
AU - for the Movement Disorder Society-Endorsed PSP Study Group
AU - Whitwell, Jennifer L.
AU - Höglinger, Günter U.
AU - Antonini, Angelo
AU - Bordelon, Yvette
AU - Boxer, Adam L.
AU - Colosimo, Carlo
AU - van Eimeren, Thilo
AU - Golbe, Lawrence I.
AU - Kassubek, Jan
AU - Kurz, Carolin
AU - Litvan, Irene
AU - Pantelyat, Alexander
AU - Rabinovici, Gil
AU - Respondek, Gesine
AU - Rominger, Axel
AU - Rowe, James B.
AU - Stamelou, Maria
AU - Josephs, Keith A.
N1 - Publisher Copyright:
© 2017 The Authors. Movement Disorders published by Wiley Periodicals, Inc. on behalf of International Parkinson and Movement Disorder Society.
PY - 2017/7
Y1 - 2017/7
N2 - PSP is a pathologically defined neurodegenerative tauopathy with a variety of clinical presentations including typical Richardson's syndrome and other variant PSP syndromes. A large body of neuroimaging research has been conducted over the past two decades, with many studies proposing different structural MRI and molecular PET/SPECT biomarkers for PSP. These include measures of brainstem, cortical and striatal atrophy, diffusion weighted and diffusion tensor imaging abnormalities, [18F] fluorodeoxyglucose PET hypometabolism, reductions in striatal dopamine imaging and, most recently, PET imaging with ligands that bind to tau. Our aim was to critically evaluate the degree to which structural and molecular neuroimaging metrics fulfill criteria for diagnostic biomarkers of PSP. We queried the PubMed, Cochrane, Medline, and PSYCInfo databases for original research articles published in English over the past 20 years using postmortem diagnosis or the NINDS-SPSP criteria as the diagnostic standard from 1996 to 2016. We define a five-level theoretical construct for the utility of neuroimaging biomarkers in PSP, with level 1 representing group-level findings, level 2 representing biomarkers with demonstrable individual-level diagnostic utility, level 3 representing biomarkers for early disease, level 4 representing surrogate biomarkers of PSP pathology, and level 5 representing definitive PSP biomarkers of PSP pathology. We discuss the degree to which each of the currently available biomarkers fit into this theoretical construct, consider the role of biomarkers in the diagnosis of Richardson's syndrome, variant PSP syndromes and autopsy confirmed PSP, and emphasize current shortfalls in the field.
AB - PSP is a pathologically defined neurodegenerative tauopathy with a variety of clinical presentations including typical Richardson's syndrome and other variant PSP syndromes. A large body of neuroimaging research has been conducted over the past two decades, with many studies proposing different structural MRI and molecular PET/SPECT biomarkers for PSP. These include measures of brainstem, cortical and striatal atrophy, diffusion weighted and diffusion tensor imaging abnormalities, [18F] fluorodeoxyglucose PET hypometabolism, reductions in striatal dopamine imaging and, most recently, PET imaging with ligands that bind to tau. Our aim was to critically evaluate the degree to which structural and molecular neuroimaging metrics fulfill criteria for diagnostic biomarkers of PSP. We queried the PubMed, Cochrane, Medline, and PSYCInfo databases for original research articles published in English over the past 20 years using postmortem diagnosis or the NINDS-SPSP criteria as the diagnostic standard from 1996 to 2016. We define a five-level theoretical construct for the utility of neuroimaging biomarkers in PSP, with level 1 representing group-level findings, level 2 representing biomarkers with demonstrable individual-level diagnostic utility, level 3 representing biomarkers for early disease, level 4 representing surrogate biomarkers of PSP pathology, and level 5 representing definitive PSP biomarkers of PSP pathology. We discuss the degree to which each of the currently available biomarkers fit into this theoretical construct, consider the role of biomarkers in the diagnosis of Richardson's syndrome, variant PSP syndromes and autopsy confirmed PSP, and emphasize current shortfalls in the field.
KW - diagnosis
KW - magnetic resonance imaging
KW - positron emission tomography
KW - progressive supranuclear palsy
KW - single-photon emission computed tomography
UR - http://www.scopus.com/inward/record.url?scp=85018927746&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85018927746&partnerID=8YFLogxK
U2 - 10.1002/mds.27038
DO - 10.1002/mds.27038
M3 - Review article
C2 - 28500751
AN - SCOPUS:85018927746
SN - 0885-3185
VL - 32
SP - 955
EP - 971
JO - Movement Disorders
JF - Movement Disorders
IS - 7
ER -